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Abstract 
Objective: This study aimed to evaluate serum leptin and high sensitivity C‑reactive protein (hsCRP) concentrations 
in obese Ghanaians with or without type 2 diabetes and to find out the extent to which their levels are influenced by 
underlying disorders.
Results: Obese subjects with type 2 diabetes had lower leptin but higher hsCRP levels compared with obese 
non‑diabetic controls. There were negative correlations within the control group for glucose vs % muscle mass 
(r = − 0.378, p = 0.016), leptin vs % muscle mass (r = − 0.555, p = 0.001) and within the obese diabetic group for 
leptin vs % muscle mass (r = − 0.602, p = 0.001). Obese persons without diabetes were about three times more likely 
to have higher leptin levels compared with their obese diabetic counterparts (Odds ratio = 3.315, p < 0.001). Obese 
females independently had a tenfold increase in leptin levels compared with obese males.
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Introduction
Chronic disorders such as obesity and diabetes mellitus 
have reached epidemic proportions globally [1–3] with 
approximately eighty percent (80%) of the populace with 
type 2 diabetes mellitus either obese or overweight [4, 
5]. Reports by International Diabetes Federation in 2015 
revealed that an estimated (3.3–6.0) % of Ghanaians aged 
20–79  years had diabetes mellitus with a further 7.8% 
being glucose impaired [1]. Inflammatory markers have 
generally been implicated in insulin resistance [6–9]. 
Leptin, a 16 kDa protein, secreted by the adipose tissue 
is a potential determinant of adiposity and risk for type 
2 diabetes [10–13]. High sensitivity C-reactive protein 
(hsCRP), an acute phase protein is synthesized by the 
liver and increases in concentration following infection, 
inflammation or trauma [9]. Levels of hsCRP have been 
observed to be increased in obese persons with diabe-
tes mellitus and correlate with measures of adiposity 
including body mass index (BMI) and waist circumfer-
ence [14, 15]. The extent to which these biomarkers 
contribute to metabolic function and/or dysfunction 
is not fully understood especially in relation to gender 
and ethnicity. The purpose of this study was to evalu-
ate serum leptin and hsCRP concentrations in Ghanaian 
obese subjects with and/or without type 2 diabetes and 
to find out the extent to which their levels are influenced 
by the underlying disorder. We hypothesized that obese 
subjects with type 2 diabetes will have higher leptin and 
hsCRP levels compared with their obese non-diabetic 
counterparts.
Main text
Methods
The study design was a cross-sectional one conducted 
among 160 obese (BMI >  30  kg/m2) Ghanaian subjects 
between October 2014 and April 2015. Study partici-
pants included 80 type 2 diabetic persons attending the 
National Diabetes Management and Research Centre 
(NDMRC), Korle-Bu, Accra and 80 age and gender-
matched obese staff/workers of the Korle-Bu Teaching 
Hospital, Accra, Ghana without diabetes mellitus. Con-
secutive subjects who agreed to the study and met the 
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criteria for inclusion were recruited. An oral glucose 
tolerance test (OGTT), regarded as diagnostic of type 
2 diabetes were performed on all volunteers. Obesity 
was defined based on BMI ≥ 30 kg/m2. Type 2 diabetes 
was confirmed by a physician at the National Diabetes 
Management and Research Centre (NDMRC), Korle-
Bu, Accra, based on results of fasting blood glucose 
≤  6.9 mmol/L and a 2 h-OGTT > 11.1 mmol/L on two 
separate occasions. Case subjects were either being life-
style managed or were on oral hypoglycemic drugs. A 
pre tested structured (Additional file  1: Questionnaire) 
was administered to assess the socio-economic status, 
medical history and medications, family history of dia-
betes mellitus, and level of physical activity of subjects. 
Habitual smokers, defined as subjects who smoked 
tobacco or other smoking products (and are still smok-
ing) continuously for at least 6 months, persons with ges-
tational diabetes, chronic illnesses (having a persistent 
ailment for more than 3  months), stroke or amputation 
were excluded from the study. Assuming an odds ratio 
of 2 among obese subjects for type 2 diabetes, at 95% 
confidence interval and a power of 80%, a sample size of 
60 persons were adequate for this study. The study was 
approved (Protocol Identification Number: MS-Et/M.6–
P3.2/2014-2015) by the Institutional Ethics and Protocol 
Review Committee of School of Medicine and Dentistry, 
College of Health Sciences, University of Ghana. Detailed 
explanations on purpose of the study, risk and benefits 
were made known to participants. Written informed 
consent was obtained from all participants. Height of all 
participants were measured using a stadiometer (Secca, 
Germany). Weight was measured using a Full Body Sen-
sor Body Composition Monitor and Scale (Omron model 
HBF-516, Omron Healthcare, USA). This scale employed 
bio-impedance analysis to compute percentage body fat 
(% body fat), percentage muscle mass (% muscle mass) 
and visceral fats. Blood pressure was taken using a mer-
cury sphygmomanometer and stethoscope after partici-
pants had rested for 15  min. Venous blood (5  mL) was 
obtained from the subjects between 07:00 and 09:00  h 
each day, after an overnight fast, according to Helsinki 
protocol declaration (2008). One milliliter (1  mL) of 
whole blood was transferred into sodium fluoride con-
taining tube and the plasma separated for the estimation 
of glucose. The remaining four milliliters (4 mL) of whole 
blood was placed into serum separator tubes for process-
ing. Resulting sera were then aliquoted in 0.5  mL por-
tions into sterile eppendorf tubes and stored at − 20  °C 
until required for use. Fasting blood glucose, total cho-
lesterol (TCHOL), triglycerides (TG), low density lipo-
protein (LDL) and high density lipoprotein cholesterol 
(HDL) were analyzed using auto-analyzer (Roche-Hitachi 
Modular Analytics, Tokyo, Japan) at the Department 
of Chemical Pathology Laboratory of the School of 
Biomedical and Allied Health Sciences, University of 
Ghana. Serum leptin and hsCRP levels were measured 
using enzyme-linked immunosorbent assay kits (Gen-
Way Biotech Inc. VA, USA) at the Public Health Refer-
ence Laboratory, Accra. A calibration curve was used 
to determine analyte concentrations from the strength 
of signal produced in the immunoassay. Unspecific sub-
strate binding was eliminated by using a specific second-
ary antibody. The GraphPad prism software version 6.0 
(San Diego California, USA) was used for statistical anal-
ysis. Values are expressed as mean ± standard deviation. 
The unpaired student t test was used for the comparison 
between means of clinical and biochemical parameters. 
Several associations were tested using Pearson’s corre-
lation co-efficient. The odds ratio with 95% confidence 
interval (CI) was calculated for all variables to determine 
their contribution to the variances in leptin levels. A 
probability level less than 5% was considered statistically 
significant.
Results
Data were obtained from 80 persons with type 2 dia-
betes (cases) and 80 persons without diabetes mellitus 
(controls). The clinical and biochemical parameters of 
the study population are shown in Table 1. Difference in 
means for age, BMI, % body fat, % muscle mass, and vis-
ceral fat, respectively between the two groups were not 
significant (p  =  0.9119, 0.2666, 0.4008, 0.1735, 0.4810). 
Case subjects had higher systolic blood pressure (SBP), 
glucose, hsCRP and lower TCHOL, LDL and leptin lev-
els, respectively (p  =  0.0001, 0.0009, 0.0036; 0.0135, 
0.0069, 0.0018) than their control counterparts. When 
categorized into severity in glucose levels, male diabetic 
persons with glucose levels > 11.0 mmol/L and between 
6.2 and 11.0  mmol/L had higher leptin and hsCRP lev-
els, respectively (p  =  0.0465; p  =  0.0203) compared 
to the other grouping (Table  1). Associations between 
several correlates with body composition parameters 
are shown in Table  2. There were negative correlation 
within the obese non-diabetic group for glucose vs % 
muscle mass (r = − 0.378, p = 0.016), leptin vs % mus-
cle mass (r = − 0.555, p = 0.001) and within the obese 
diabetic group for leptin vs % muscle mass (r = − 0.602, 
p =  0.001). Positive associations were observed for glu-
cose vs % body fat (r = 0.315, p = 0.048), % body fat vs 
leptin (r =  0.572, p =  0.001), BMI vs leptin (r =  0.444, 
p = 0.004) within the control group and leptin vs % body 
fat (r  =  0.635, p  =  0.001) within the case group. Risk 
assessment of leptin levels in this study are provided in 
Table  3. Obese persons with diabetes were about three 
times more likely to have lower leptin levels than their 
obese non-diabetic counterparts (Odds ratio  =  3.315, 
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CI  =  1.918, 5.824; p  <  0.001). Further, obese women, 
independent of other factors were about 10 times more 
likely to have higher leptin levels than obese men (Odds 
ratio = 9.750, CI = 4.461, 21.311; p < 0.001).  
Discussion
Obesity is a major contributor to the burden of meta-
bolic dysfunction and to several chronic diseases 
including type 2 diabetes [1]. In the southern parts of 
Ghana, especially in the Greater Accra region and its 
environs, the prevalence of obesity and type 2 diabe-
tes have been reported to be increasing steadily [2, 16]. 
What is not clear is the contributory effects of gender, 
physical activity and diabetes mellitus on obesity. The 
present study evaluated the impact of serum leptin and 
hsCRP levels in obese Ghanaian subjects with and/
or without type 2 diabetes. In this study, obese sub-
jects with type 2 diabetes had lower serum leptin but 
higher hsCRP concentrations than obese non-diabetic 
individuals. Multivariate analysis further revealed that, 
obese persons with type 2 diabetes were three times 
less likely to have elevated leptin levels than obese con-
trols. Further, obese diabetic men in this study, with 
poor glycemic control, had lower leptin levels. A pos-
sible explanation for reduced leptin levels in persons 
with type 2 diabetes may be due to insulin resistance, a 
modulator of leptin production. Thus defect in glucose 
sensing, as seen in type 2 diabetes could be responsible 
Table 1 Clinical and biochemical measurements of study participants
Values are given as mean ± standard deviation
Categorized glucose grouping by one way ANOVA
Italic results indicate significant relationships
M male; F is female; SBP systolic blood pressure; DBP diastolic blood pressure; TCHOL total cholesterol; TG triglyceride; HDL high density lipoprotein; LDL low density 
lipoprotein; BMI body mass index; hsCRP high sensitivity C-reactive protein; CR coronary risk; % percentage
a, b Denotes differences between groups. p < 0.05 is statistically significant
Variables Obese subjects p value
Diabetics (80) Non-diabetics (80)
Age 48.60 ± 5.928 48.40 ± 7.877 0.9119
Sex (M/F) 30/50 30/50
Height (cm) 172.2 ± 9.996 168.6 ± 4.623 0.0734
Weight (kg) 98.55 ± 18.53 91.30 ± 8.952 0.0586
BMI (kg/m2) 34.08 ± 2.97 33.13 ± 2.361 0.2666
% Body fat 30.19 ± 7.319 31.47 ± 3.969 0.4008
% Muscle mass 32.72 ± 3.009 31.64 ± 3.062 0.1735
Visceral fat 16.00 ± 4.202 15.27 ± 3.796 0.4810
SBP (mmHg) 138.4 ± 9.027 126.9 ± 7.780 0.0001
DBP (mmHg) 85.87 ± 8.295 83.53 ± 6.684 0.2351
Glucose (mmol/L) 6.500 ± 2.956 4.947 ± 0.739 0.0009
TCHOL (mmol/L) 4.369 ± 0.898 5.059 ± 1.181 0.0135
TG (mmol/L) 1.515 ± 1.206 1.366 ± 0.745 0.5678
HDL (mmol/L) 1.019 ± 0.202 1.021 ± 0.275 0.9830
LDL (mmol/L) 2.724 ± 0.744 3.345 ± 0.959 0.0069
CR (ratio) 4.437 ± 1.259 5.158 ± 1.399 0.0402
Leptin (ng/ml) 13.84 ± 4.759 17.92 ± 5.506 0.0018
hsCRP (ng/ml) 0.256 ± 0.108 0.184 ± 0.106 0.0036
Variables Glucose level among diabetic subjects p value
3.6–6.19 mmol/L 6.2–11.0 mmol/L > 11.0 mmol/L
Male
 Leptin 10.33 ± 4.08b 10.14 ± 1.88b 6.000 ± 0.71a 0.0465
 hsCRP 0.193 ± 0.09b 0.314 ± 0.12a 0.150 ± 0.02b 0.0203
Female
 Leptin 14.60 ± 3.19 15.95 ± 3.86 15.83 ± 2.021 0.3484
 hsCRP 0.301 ± 0.10 0.264 ± 0.13 0.202 ± 0.138 0.4913
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for the lower leptin production, suggesting a signalling 
crosstalk in glucose regulation. Altered body fat distri-
bution in diabetic subjects have been suggested as an 
alternative explanation for lowered leptin levels [17–
20]. Even though this study did not observe differences 
in visceral fat among the two groups, leptin levels cor-
related positively with measures of adiposity and body 
composition in both groups indicating a possible syner-
gistic effect. A third explanation could be due to the use 
of statin medications. Twelve (12) of our case subjects 
were on lipid lowering drugs and this could have con-
tributed to such an observation. Result however were 
not statistically significantly when we excluded those on 
lipid lowering drugs from the analysis. Serum leptin lev-
els in this study was also influenced by gender. Obese 
females were about 10 times more likely to have higher 
leptin levels than obese males. Stimulation of leptin 
mRNA production by 17β-estradiol in females could 
explain the above observation [21]. An inverse relation-
ship has also been observed in a male cohort for leptin 
versus testosterone levels [22]. Levels of hsCRP among 
obese persons with type 2 diabetes in this study, was 
significantly higher than controls suggesting a possible 
directional relationship between insulin resistance and 
chronic inflammation. Whereas this study showed no 
variations in body composition, prior studies showed 
a strong association between hsCRP and measures of 
central obesity [23]. In summary, results highlight rela-
tionships of leptin and hsCRP with obesity and type 2 
diabetes. We demonstrated that type 2 diabetes and 
gender were independent factors in determining serum 
leptin levels among obese subjects.
Table 2 Association between biochemical indices and body composition parameters
Table 2 shows the association between several correlates with body composition
Italic results indicate significant relationships
TCHOL total cholesterol; HDL high density lipoprotein; LDL low density lipoprotein; VLDL very low density lipoprotein; TG triglyceride; BMI body mass index; hsCRP high 
sensitivity C-reactive protein; CR coronary risk
Variables Control group (obese non-diabetics (80) Case group (obese diabetics (80)
BMI Body fat Muscle mass Visceral fat BMI Body fat Muscle mass Visceral fat
Glucose
 r 0.258 0.315 − 0.378 ‑0.091 0.077 0.104 − 0.080 0.145
 p 0.107 0.048 0.016 0.579 0.636 0.525 0.624 0.373
TCHOL
 r − 0.004 − 0.138 0.195 0.300 0.078 0.004 0.022 − 0.077
 p 0.981 0.397 0.229 0.060 0.633 0.979 0.895 0.638
TG
 r 0.025 − 0.301 0.351 0.504 0.075 − 0.178 0.197 0.222
 p 0.878 0.059 0.026 0.001 0.644 0.271 0.224 0.169
HDL
 r − 0.227 0.165 − 0.160 − 0.179 − 0.033 0.117 − 0.101 − 0.230
 p 0.159 0.310 0.325 0.357 0.841 0.473 0.535 0.153
LDL
 r 0.131 − 0.057 0.125 0.292 0.075 0.024 − 0.004 − 0.090
 p 0.421 0.727 0.443 0.067 0.645 0.884 0.978 0.579
VLDL
 r 0.029 − 0.303 0.355 0.515 0.076 − 0.184 0.204 0.222
 p 0.858 0.058 0.025 0.001 0.641 0.255 0.207 0.169
CR
 r 0.278 − 0.166 0.242 0.350 0.044 − 0.070 0.062 0.076
 p 0.082 0.306 0.133 0.027 0.786 0.668 0.705 0.639
Leptin
 r 0.444 0.572 − 0.555 − 0.114 0.237 0.635 − 0.602 − 0.144
 p 0.004 0.001 0.001 0.483 0.141 0.001 0.001 0.377
hsCRP
 r 0.033 0.211 − 0.158 − 0.005 0.172 0.113 − 0.035 0.125
 p 0.840 0.191 0.329 0.973 0.289 0.489 0.830 0.443
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Limitations
This study had some limitations. Although the authors 
primarily focused on obese subjects, a normal weight 
control group would have been useful in a cross-sectional 
comparison manner. Another limitation was our inability 
to measure the insulin resistant state of our subjects. Fur-
ther, the authors could not measure glycated hemoglobin 
(HbA1c), a marker that could have provided information 
on diabetes management. Future studies should focus 
on large population-based longitudinal studies to under-
stand with change over time, the mechanistic role of adi-
pocytokines in obesity and related disorders.
Additional file
Additional file 1: Questionnarie. Study questionnaire. This file contains 
the pre‑tested questionnaire used in the study.
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